MedTrace Logo

A Bioequivalence Study of Levetiracetam Versus Keppra

NCT00926302 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2009-06-23

No results posted yet for this study

Summary

The purpose of this study is to assess the bioequivalence of Levetiracetam versus Keppra administered under fasting conditions to healthy adult subjects.

Conditions

  • Healthy

Interventions

DRUG

Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)

Levetiracetam 500mg/tablet Oral once

DRUG

Keppra (Levetiracetam - USB SA Pharma Sector)

Levetiracetam 500mg/tablet oral once

Sponsors & Collaborators

  • Tri-Service General Hospital

    lead OTHER

Principal Investigators

  • I-Shin Shiah, M.D. · Tri-Service General Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-02-28
Completion
2009-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926302 on ClinicalTrials.gov